Cleveland BioLabs Inc.

Buffalo, NY, United States

Cleveland BioLabs Inc.

Buffalo, NY, United States

Time filter

Source Type

Patent
Cleveland BioLabs Inc. | Date: 2016-08-19

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.


Patent
Cleveland BioLabs Inc. | Date: 2017-06-07

The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.


Patent
Cleveland BioLabs Inc. | Date: 2017-06-07

The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.


Patent
Cleveland BioLabs Inc. and Cleveland Clinic | Date: 2015-03-11

The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin


Patent
Cleveland BioLabs Inc. and Cleveland Clinic | Date: 2013-07-15

The use of lipopeptides as inducers of NF-B for the protection of mammals from the effects of apoptosis is described.


Patent
Cleveland Clinic and Cleveland BioLabs Inc. | Date: 2015-03-06

The use of lipopeptides as inducers of NF-B for the protection of mammals from the effects of apoptosis is described.


Patent
Cleveland BioLabs Inc. | Date: 2015-03-04

A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and elsewhere, and increasing the number of differentiating hematopoietic stem cells in the bloodstream.


Provided are compositions and methods for prophylaxis and/or therapy of dermal damage. The compositions and methods involve Toll like receptor (TLR) agonists that can inhibit the formation or accelerate healing of dermal damage, and/or inhibit inflammation at near the location of the dermal damage. The TLR agonists can be TLR2 and/or TLR5 agonists. The compositions and methods are suitable for prophylaxis and/or therapy of dermal damage caused by radiation, or non-radiation thermal injury such as burns caused by contact with heated surfaces or heated objects, light, and for disruptions in integument resulting in cuts, such as incisions, or punctures. The compositions can be used topically, subcutaneously or systemically. Articles of manufacture coated or impregnated with TLR agonist(s) are also provided.


Patent
Cleveland BioLabs Inc. | Date: 2013-07-02

A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and elsewhere, and increasing the number of differentiating hematopoietic stem cells in the bloodstream.


Patent
Cleveland BioLabs Inc. | Date: 2015-11-23

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Loading Cleveland BioLabs Inc. collaborators
Loading Cleveland BioLabs Inc. collaborators